JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral to an Overweight rating, boosting the price target to $11 from $10. The change follows the solid results of Recursion’s MEK 1/2 inhibitor, REC-4881, which showed potent effectiveness in FAP patients during the TUPELO trial.

After 12 weeks of treatment, the trial showed a 43% median reduction in total polyp burden, with 75% of evaluable patients experiencing reductions. Notably, 82% of patients sustained stable decreases 12 weeks after discontinuing medication, with a median reduction of 53% from baseline.

JPMorgan sees explosive potential for REC-4881 in the United States, projecting peak sales of more than $1 billion with a 60% chance of success. These clinical outcomes, as well as pharmaceutical agreements that have produced more than $500 million in milestone payments to date, have helped to confirm Recursion’s AI-driven pipeline.

According to the firm’s study, growing patient groups, stronger penetration rates, and pricing might all provide additional upside for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and machine learning to accelerate drug discovery, with a focus on rare diseases and oncology.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.